GnRH (Gonadotropin-Releasing Hormone)

Mechanism

Pulsatile binding to pituitary GnRH receptors triggers LH and FSH release; continuous exposure desensitises the receptor.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

• Pituitary function testing
• Hypogonadism research
• Reproductive endocrinology context

Literature on file 10

• review or editorial
  Adenomyosis and fertility: from pathophysiology to optimizing reproductive outcomes. graded on: indexed as "Review" - secondary literature, not a study — “Review”
• animal in vivo
  Combined HS6ST1 and HS6ST2 loss disrupts the formation and migration of gonadotropin-releasing hormone neurons. graded on: an animal model — read from the indexed abstract — “mice”
• human observational
  Long-Term Outcomes of Gonadotropin-Releasing Hormone Analogue Therapy in Central Precocious Puberty: A Comparative Analysis of Obese and Normal-Weight Girls. graded on: retrospective comparative cohort, obese vs normal-weight girls on GnRH analogue — read from the abstract — “abstract review”
• animal in vivo
  Single-nuclei RNA sequencing reveals heterogeneity within developing GnRH3 neurons in zebrafish. graded on: an animal model — “zebrafish”
• human observational
  NCT00586898: Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle graded on: a registered clinical study — “clinicaltrials.gov”
• human observational
  NCT00587431: Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer graded on: a registered clinical study — “clinicaltrials.gov”
• human observational
  NCT02956447: Administration of Kisspeptin in Patients With Hyperprolactinemia graded on: a registered clinical study — “clinicaltrials.gov”
• human RCT
  NCT04037254: Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I) graded on: a randomised trial — “Randomized Phase II Trial”
• human observational
  NCT01381016: Estrogen Sensitivity and Ovulatory Dysfunction in Obesity graded on: a registered clinical study — “clinicaltrials.gov”

Not graded

1 citation whose study design could not be read from the title. Left ungraded rather than guessed at.

• not graded
  Gonadotropin-Releasing Hormone (2011)

Identity

PubChem CID 16132914 computed 3D conformer

Skeletal formulathe canonical depiction

Drawn by PubChem from CID 16132914, the identifier on this record.

Molecular weight

1212.3

Molecular formula

C60H73N15O13

PubChem CID

16132914

UniProt

P01148 (precursor)

InChI key

NMJREATYWWNIKX-UHFFFAOYSA-N

Sequence

XHWSYGWLPG

SMILES

CC(C)CC(C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)CNC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8

InChI

InChI=1S/C60H73N15O13/c1-32(2)20-47(60(88)75-19-7-12-49(75)59(87)65-28-50(61)78)73-55(83)44(22-34-25-63-40-10-5-3-8-38(34)40)69-52(80)29-66-53(81)43(21-33-13-15-37(77)16-14-33)70-58(86)48(30-76)74-56(84)45(23-35-26-64-41-11-6-4-9-39(35)41)71-57(85)46(24-36-27-62-31-67-36)72-54(82)42-17-18-51(79)68-42/h3-6,8-11,13-16,25-27,31-32,42-49,63-64,76-77H,7,12,17-24,28-30H2,1-2H3,(H2,61,78)(H,62,67)(H,65,87)(H,66,81)(H,68,79)(H,69,80)(H,70,86)(H,71,85)(H,72,82)(H,73,83)(H,74,84)

Listed prices 10

What 10 shops we track listed for GnRH (Gonadotropin-Releasing Hormone), read from their own public catalogues on 2026-09-14. We take no commission on these and they are not ranked by any payment — how vendors are scored.

Share this record